{"raw_mentions": "Anandamide evidencing a preferential affinity for CB1 binding, for example having a Ki for CB1 of less than 100nM and a Ki for CB2 of more than 1000nM."}
{"final_json": [{"molecule_name": "Anandamide", "protein_target_name": "CB1", "binding_metric": "Ki", "value": "<100", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "Anandamide", "protein_target_name": "CB2", "binding_metric": "Ki", "value": ">1000", "unit": "nM", "is_logarithmic": false}]}
{"raw_mentions": "Anandamide analogs for use in the present formulations may be characterized by receptor binding activities, for example being one or more of: partial agonists of the CBi receptor; weak partial agonists of the CB2 receptor, partial agonists of vanilloid receptor VR1 ; and/or an agonistic ligand of the GPR55 receptor. \nAlternatively, the binding affinity of anandamide analogs for the CB1 and CB2 receptors may be characterized by a preferential affinity for CB1 binding, for example having a Ki for CB1 of less than 10nM and a Ki for CB2 of more than 100nM."}
{"final_json": [{"molecule_name": "anandamide analogs", "protein_target_name": "CB1 receptor", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "anandamide analogs", "protein_target_name": "CB2 receptor", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "anandamide analogs", "protein_target_name": "vanilloid receptor VR1", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "anandamide analogs", "protein_target_name": "GPR55 receptor", "binding_metric": null, "value": null, "unit": null, "is_logarithmic": false}, {"molecule_name": "anandamide analogs", "protein_target_name": "CB1 receptor", "binding_metric": "Ki", "value": "<10", "unit": "nM", "is_logarithmic": false}, {"molecule_name": "anandamide analogs", "protein_target_name": "CB2 receptor", "binding_metric": "Ki", "value": ">100", "unit": "nM", "is_logarithmic": false}]}
